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Abstract
Background: The implantation of mechanical circulatory support devices in heart failure patients is associated with
a systemic inflammatory response, potentially leading to death from multiple organ dysfunction syndrome. Previous
studies point to the involvement of many mechanisms, but an integrative hypothesis does not yet exist. Using
time-dependent whole-genome mRNA expression in circulating leukocytes, we constructed a systems-model to
improve mechanistic understanding and prediction of adverse outcomes.
Methods: We sampled peripheral blood mononuclear cells from 22 consecutive patients undergoing mechanical
circulatory support device (MCS) surgery, at 5 timepoints: day −1 preoperative, and postoperative days 1, 3, 5, and
8. Clinical phenotyping was performed using 12 clinical parameters, 2 organ dysfunction scoring systems, and
survival outcomes. We constructed a strictly phenotype-driven time-dependent non-supervised systems-
representation using weighted gene co-expression network analysis, and annotated eigengenes using gene
ontology, pathway, and transcription factor binding site enrichment analyses. Genes and eigengenes were mapped
to the clinical phenotype using a linear mixed-effect model, with Cox models also fit at each timepoint to survival
outcomes.
Results: We inferred a 19-module network, in which most module eigengenes correlated with at least one aspect
of the clinical phenotype. We observed a response of advanced heart failure patients to surgery orchestrated into
stages: first, activation of the innate immune response, followed by anti-inflammation, and finally reparative
processes such as mitosis, coagulation, and apoptosis. Eigengenes related to red blood cell production and
extracellular matrix degradation became predictors of survival late in the timecourse corresponding to multiorgan
dysfunction and disseminated intravascular coagulation.
Conclusions: Our model provides an integrative representation of leukocyte biology during the systemic
inflammatory response following MCS device implantation. It demonstrates consistency with previous hypotheses,
identifying a number of known mechanisms. At the same time, it suggests novel hypotheses about time-specific
targets.
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Background
Mechanical circulatory support (MCS) device therapy is
a treatment option for patients with advanced heart fail-
ure (AdHF). It consists of surgical implantation of a
mechanical device to assist or replace cardiac function
and restore normal hemodynamics. It is commonly used
as a bridge to heart transplantation for patients deterior-
ating while awaiting an organ transplant, as a bridge to
recovery when myocardial function can still be restored,
and as lifelong (destination) therapy for patients who are
not candidates for transplantation [1]. The physiological
rationale underlying the treatment is that by restoring
normal hemodynamics, it is possible to at least partially
restore systemic functions such as oxygen metabolism
and neurohormonal regulation, which in turn reduces
hypoxia and inflammation, and improves the function of
all organs promoting the recovery of the heart failure
patient [2].
However, up to 20% of AdHF-patients die during the
first year post MCS-surgery. Surgical implantation of the
device is a major procedure, associated with a systemic
inflammatory response, which most often is self-limited
but lack of self-control can potentially lead to an uncon-
trollable inflammatory response, acute organ dysfunc-
tion, and ultimately to patient’s death. Clinically, patients
develop a cascade of complications, including hepatic,
renal, pulmonary, immunologic, hematologic, gastro-
intestinal, metabolic and neurologic dysfunction. It is
presumed that an altered immune response induced by
both the MCS device and surgery, facilitated by the pre-
existing HF syndrome [3] and its sequentially escalating
stages of compensation first described more than
50 years ago [4], is responsible. The leading cause of
mortality in intensive care units and the most feared
consequence of this systemic inflammatory response is
the Multiple Organ Dysfunction Syndrome (MOD) [5].
Heart failure (HF), initiated by various mechanisms,
leads to compensatory chronic upregulation of sympa-
thetic nervous system (SNS) and renin-angiotensin-
aldosterone system (RAAS) activity in an attempt to
maintain BP, cardiac output (CO) and oxygen delivery
(O2). Further progression of myocardial injury and HF
progression leads to reduced CO and O2–delivery to or-
gans/tissues. This triggers, hypothetically via organ-
specific endothelial cell (EC)/platelet (PLT)/peripheral
blood mononuclear cell (PBMC) interactions, compensa-
tory immune system activation, first described by meas-
uring elevated tumor-necrosis factor –alpha levels in
patients with most severe HF [6], that hypothetically
serves to provide short-term compensation for the fail-
ing heart. This increasing immune system activation co-
incides with worsening organ dysfunction of the kidneys
(higher creatinine, Cr), liver (higher bilirubin, Bili), bone
marrow (lower platelets) and brain (worse Glasgow
Coma Scale, GCS). In this milieu, therapies such as the
implantation of MCS restore normal CO and O2–deliv-
ery to the organs yet are associated with an unpredict-
able inflammatory state transition, and associated risk of
organ dysfunction and death [1, 7, 8] (Fig. 1).
It is thought that activation of the immune -associated
inflammatory and coagulation pathway produces a fibrin
matrix that blocks blood flow in the microcirculation
causing tissue necrosis, ultimately leading to organ fail-
ure [9]. Few therapeutic options are currently established
to help reduce this risk, as most aspects of the progres-
sion to MOD are not well understood. For example,
anti-inflammatory measures such as glucocorticoids
have yielded mixed results [10], and are therefore not
routinely used in the management of these patients. Suc-
cessful therapeutic strategies apparently require the un-
derstanding of the multiple systems involved and the
factors controlling their emergent properties or effects.
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Fig. 1 Neuro-Endocrino-Immuno-Pathophysiology Of Heart Failure.
HF: Heart failure (HF) is initiated by various mechanisms. HF leads to
lower mean arterial pressure (BP-) and compensatory upregulation
of sympathetic nervous system (SNS) and renin-angiotensin-
aldosterone system (RAAS) in an attempt to maintain BP, cardiac
output (CO) and oxygen delivery (O2). Further myocardial injury
leads to HF progression and reduced CO (CO-) and O2–delivery
(O2-) to organs/tissues. This triggers, hypothetically via organ-specific
endothelial cell/platelet/peripheral blood mononuclear cell
(PBMC) interactions, compensatory immune system activation
that serves to provide shortterm compensation for the failing
heart. This increasing immune system activation coincides with
worsening organ dysfunction of the kidneys (higher creatinine,
Cr+), liver (higher bilirubin, Bili+), bone marrow (lower platelets,
Plt-) and brain (worse Glasgow Coma Scale, GCS-). In this milieu,
the surgical implantation of therapies such as mechanical circulatory
support (MCS) restore normal CO and O2–delivery to the organs yet
are associated with an unpredictable inflammatory state transition. This
makes the prediction of a future survivor/non-survivor outcome
challenging. We hypothesize that time-dependent NGS-based
PBMC-biology analysis, when added to current clinical predictors,
improve prediction precision of future survivor/non-survivor outcome
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A significant amount of work has been done examin-
ing similar therapies for systemic infection, i.e. sepsis–
related MOD [11]. In both sepsis- and MCS-related
MOD, the interplay between leukocytes, platelets, and
endothelium is thought to play a critical role in mediat-
ing the phenotype [12, 13], and so many of the strategies
are understood as affecting various aspects of the endo-
thelial response to inflammatory injury. For example, a
number of clinical trials have been conducted to evaluate
therapies targeted at controlling cell adhesion, coagula-
tion cascade and apoptosis such as transcription factors
like NF-κB; signaling pathways such as MAPK; or vaso-
active drugs to counteract the vascular endothelial re-
sponse to inflammation such as nitric oxide synthase
inhibitors [14]. Unfortunately, most interventions have
failed to improve outcomes, leaving much work to be
done researching new therapeutic targets but also identi-
fying new approaches to understand the system and its
controlling factors to be able to intervene using a
systems-based strategy.
There is currently no hypothesis about the integrative
systems biology in MCS-related MOD, a key element to
understand the evolution of a phenotype and develop-
ment of new therapeutic strategies. The coordination of
all these features has yet to be contextualized, and many
questions remain about how they are orchestrated to-
gether as a time-evolving system. Analysis of phenotype-
driven longitudinal whole-genome mRNA expression in
circulating leukocytes offers a way to synchronously
conceptualize all of these known features, while also fa-
cilitating discovery of novel elements. Several machine
learning and bioinformatics tools are available to assist
in statistical modeling of high-dimensional data, and
have yielded promising results in many genomic studies.
These methods allow for discovery of interesting tem-
poral modifications of the biology of the immune re-
sponse and recovery process, and identify systemic
motifs that are of clinical importance.
In this article, we apply whole-genome mRNA gene
expression profiling in circulating peripheral blood
mononuclear cells (PBMC). PBMC is commonly used to
study leukocyte gene expression because it is easily ac-
cessible and includes several key inflammatory cell pop-
ulations that play a central role in the orchestration of
the immune response during health and disease. To re-
construct the temporal dynamics in response to surgery
during the critical early hazard period, we analyzed a
time-series of samples taken at baseline and during the
early and most critical period of the MCS therapy creat-
ing a 5 time-point time-course study conducted in the
sickest patients suffering of AdHF. Because most of the
dynamic response to surgery occurs in the first postop-
erative week, it is expected that patient trajectories are
most sensitive and informative during this window. Our
analysis strategy then uses machine learning to gain a
comprehensive picture of the systems biology and its re-
lation to time-dependent clinical phenotypes and
outcomes.
Methods
Patients
We collected blood samples from 22 consecutive AdHF
patients admitted to our hospital undergoing MCS be-
tween March 2013 and September 2014. Samples were
collected at 5 timepoints: day −1 preoperative, and post-
operative days 1, 3, 5, and 8. The study was conducted
under UCLA IRB 12–000351 approval and all patients
signed informed consent to participate. To address to
most pressing clinical problem of MCS-related peri-
operative MOD [1, 7, 8], we chose to base this analysis
on AdHF-patients undergoing MCS-surgery alone.
Clinical management
All study participants were referred to the UCLA Inte-
grated AdHF Program and evaluated for the various
therapeutic options, including continued optimal med-
ical management, MCS, and heart transplantation. All
study participants were recommended by the multidis-
ciplinary heart transplant selection committee to
undergo MCS-surgery therapy, and consented to
proceed. Preoperatively, n = 2 patients were in a state of
critical cardiogenic shock (Interagency Registry for
Mechanically Assisted Circulatory Support (INTER-
MACS) class 1); n = 12 patients were progressively de-
clining despite being on inotropic support
(INTERMACS class 2); n = 7 patients were stable but
inotrope dependent (INTERMACS class 3); and n = 1
patient had resting failure symptoms (INTERMACS
class 4) [1]. All patients were optimized regarding med-
ical heart failure therapy, and underwent MCS-therapy
according to established guidelines [15, 16].
After anesthesia induction, patients were intubated
and placed on cardiopulmonary bypass. The type of
MCS-device selected depended on the acuity and sever-
ity of the heart failure syndrome as well as patient char-
acteristics [17]. For left ventricular support, patients
underwent either Heartmate II (HeartMate II® pumps
are valveless, rotary, continuous flow pumps) or HVAD
(HeartWare® HVAD pumps are valveless, centrifugal,
continuous flow pumps). For biventricular support, pa-
tients underwent either Centrimag-BVAD (Centrimag®
pumps are valveless, centrifugal, continuous flow pumps
that are external to the body), PVAD biventricular assist
device (BVAD) (Thoratec® Paracorporeal Ventricular As-
sist Device (PVAD) pumps each contain two mechanical
tilting disk valves) or the t-TAH (the Temporary Total
Artificial Heart consists of two artificial ventricles that
are used to replace the failing heart).
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Various combinations of cardiovascular inotropic and
vasoactive drugs were used to support patient’s
hemodynamics postoperatively, tailored to individualized
requirements. In addition, other temporary organ system
support was administered as required (e.g. mechanical
ventilation, hemodialysis, blood transfusions, antibiotic
therapy).
Clinical phenotyping
Demographic variables were obtained for all patients,
and we also collected 12 distinct parameters on a daily
basis for time-dependent clinical phenotyping of the pa-
tient cohort. At each timepoint, a comprehensive set of
clinical variables to assess multiple organ dysfunction
were recovered from patient records including: serum
bilirubin, serum creatinine, leukocyte count, platelet
count, alveolar oxygen pressure, fraction of inspired oxy-
gen (FiO2), mean systemic arterial pressure (MAP), INR
(International Normalized Ratio, for prothrombin time),
blood glucose, heart rate, respiratory rate, temperature,
and the Glasgow Coma Scale (GCS).
Using combinations of these parameters, we also cal-
culated two validated and commonly used composite
organ dysfunction scores, the Sequential Organ Failure
Assessment (SOFA) score [18] and Model of Endstage
Liver Disease without except International Normalized
Ratio (INR) (MELD-XI) [19]. The SOFA score is a vali-
dated and widely accepted measure that rates degree of
organ failure across 6 major organ systems (cardiovascu-
lar, respiratory, neurological, renal, hepatic, and coagula-
tion). The MELD-XI score is a variation of the MELD
score that uses only the bilirubin and creatinine levels,
and eliminates the INR, which is typically not interpret-
able in these patients given the need of anticoagulation.
Additional information can be found in Additional file 1.
Sample processing
Sample collection and RNA isolation
Phlebotomy was performed at prespecified timepoints
including day −1 preoperative, and postoperative days 1,
3, 5, and 8. Mononuclear cells were isolated from 8 ml
of blood collected by Vacutainer Cell Preparation Tubes
(CPT) with sodium citrate (Becton Dickinson, Franklin
Lakes, NJ) and resuspended in RNA Protect (Qiagen,
Valencia, CA) within 2 h of phlebotomy. Based on the
successful AlloMapTM test development which was the
first FDA-cleared PBMC-GEP-based In-Vitro-Diagnostic
Multivariate Index Assay (IVDMIA) that maps the inter-
action of a transplanted heart’s allo-endothelial cells with
the recipient’s leukocytes [20, 21] and preliminary data
for the current project [22, 23] and its planned clinical
utility, we chose the same mixed PBMC population,
refraining from isolated subpopulation analyses.
We collected blood in Vacutainer Cell Preparation
Tubes (CPT) with sodium citrate (Becton Dickinson,
Franklin Lakes, NJ). Peripheral blood mononuclear cells
(PBMC) were isolated using manufactural protocol. In
short: Samples were processed within 2 h after blood
collection. The CPT tube was centrifuged at room
temperature (22 °C) for 20 min at 3000RPM or
2000RCF. Plasma was separated without disturbing the
cell layer. The cell layer was collected, washed with
Phosphate Buffered Solution (PBS)(Thermo Fisher Sci-
entific, Woodlend Hills, CA), and centrifuged again for
20 min at 1135 RMP or 300RCF at 22 °C. The super-
natant was aspirated, the pellet was washed with PBS,
and centrifuged for 20 min at 5.6 RPM at 4 °C. The
supernatant was discarded. The pellet was dissolved in
0.5 ml of RNA protect (Qiagen, Valencia, CA), frozen,
and stored at -80 °C. The RNA was isolated from the
PBMC using RNeasy Mini Kit (Qiagen, Valencia, CA).
The purity and concentration of the RNA was checked
by NanoDrop® ND-1000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE).. The concentration was
50 ng/ml. The purity was 260/280 ~ 2.0. The integrity of
the RNA was analyzed by Agilent® 2100 Bioanalyzer
(Agilent Technologies, Palo Alto, CA);. RIN > 9.0 and
average > 9.5.
RNA processing and analysis
After RNA extraction, quantification and quality as-
sessment, total mRNA was amplified and subjected to
NGS transcriptome analysis on the Illumina
HiSeq2000 TruSeq. Data was then subjected to quan-
tile normalization using GenomeStudio (Illumina, San
Diego, CA). Batch effects were removed using the
‘ComBat’ algorithm in R [24].
Prior to analysis, the entire set of mRNA transcripts
(39,740) was filtered by variance and entropy criteria to
remove uninformative transcripts. Filtering improves the
interpretability of the network analysis, as well as re-
duces the bias in cluster analysis [25]. We therefore first
removed genes with zero variance, and then placed cuts
on the remaining transcripts to remove the lower 30th
quantiles, reducing our list of transcripts to 14,753.
Statistical analysis
We used weighted gene co-expression network analysis
(WGNCA) [26] to compute clustered co-expressed gene
modules and infer an eigengene network. The eigengene
approach offers a powerful way to reduce dimensionality
while maintaining biological interpretability, effectively
de-noising the data for a larger systems analysis. The re-
sult provides a useful framework for relational and
mechanistic reasoning.
We interpreted the eigengenes by statistically relating
them to clinical and biological features. We inferred
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each module’s clinical relevance using a linear mixed-
effect model, connecting the module eigengenes to the
panel of day-to-day clinical parameters. We then in-
ferred the biological relevance of each module using bio-
informatics tools: gene ontology (GOSim [27]), pathway
(Strand NGS [28]), and transcription factor binding site
(rVista [29]) enrichment analyses.
We then inferred temporal patterns in both the
eigengenes and clinical parameters by standardizing
the median levels over time into z-scores, and exam-
ining each temporal slice to identify salient features.
We related these features to survival outcomes using
a multivariate Cox mixed-effect model to look for
overall module effects, and separate univariate Cox
models for each timepoint. Additional details can be
found in Additional file 1.
Results
Clinical phenotyping
Main demographic characteristics of the study patient
cohort are summarized in Table 1. Of 22 patients under-
going MCS-surgery, 5 patients died on the MCS device
at 32 (20-50) days after surgery, where we report results
in the usual format of median (interquartile range). The
17 survivors were followed until transplant (n = 13) for
107 (61–220) days or end of follow-up (December 31,
2014) (n = 4) for 600 (260–799) days. All non-survivors
were male, and a higher fraction of non-survivors had
an underlying ischemic etiology.
Principal component analysis revealed differences
between survivors and non-survivors, and their clin-
ical trajectories over time. In the biplot (Fig. 2a), clin-
ically related parameters have a similar orientation
vector, e.g. MELD-XI, SOFA, creatinine and bilirubin
cluster together, forming an organ dysfunction axis
along the first principal component. Additionally,
anti-correlated variables have opposing orientations
(e.g. GCS is antiparallel to the SOFA score, because
the GCS is a descending scale where low scores indi-
cate advanced organ dysfunction), and independent
variables are orthogonal (e.g. heart rate, respiratory
rate, and MAP appear to be somewhat independent
of organ dysfunction, aligned with the second princi-
pal component). There is a clear separation between sur-
vivors and non-survivors along the SOFA and MELD-XI
dimensions. This is expected, as non-survivors have over-
all worse organ dysfunction scores. However, the first
timestep is towards increasing organ dysfunction in both
survivors and non-survivors, indicating that all patients
suffer from a decline in organ dysfunction in immediate
response to surgery. Note that each subsequent timestep
walks toward improving organ function in survivors yet
not in non-survivors, who take a step back toward organ
dysfunction by day +8.
Table 1 Main characteristics of the study samples
Characteristic Total Survivors Non-survivors p-value
Gender Male 17 12 5 0.29
Female 5 5 0
Race White or Caucasian 17 13 4 1
Black or African American 2 2 0
Other 3 2 1
Age Median (IQR) 62.5 (42–66.5) 61 (38.5–65) 65 (62.5–76) 0.085
Etiology Ischemic 6 2 4 0.009
Non-Ischemic 16 15 1
Diabetes Diabetic 7 6 1 1
Non-Diabetic 15 11 4
INTERMACS 1 (Critical cardiogenic shock) 2 1 1 0.23
2 (Progressive decline) 12 10 2
3 (Stable, but inotrope dependent) 7 6 1
4 (Resting symptoms) 1 0 1
MCS Device HeartMate II 13 11 2 0.25
HeartWare 1 1 0
HeartMate II, CentriMag 4 2 2
TAH 1 1 0
PVAD 2 2 0
CentriMag BVAD 1 0 1
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We can construct a more detailed picture of the clin-
ical trajectory by examining how parameters peak at dif-
ferent times (Fig. 2b). On the day following surgery, we
see the SOFA score peak, while the platelet count,
temperature, and respiratory rate trough. The white
blood cell count reaches its maximum on day +3, and
then recovery occurs on day +5 and +8 as the platelet
count rises and the SOFA score decreases. All time-
dependent features are summarized in Table 2.
Finally, we discovered more detailed differences be-
tween survivors and non-survivors using a Cox model
(Fig. 2c). We found that the organ dysfunction scores
(SOFA and MELD-XI), driven by bilirubin and creatin-
ine, became more predictive of survival at later time-
points. This is expected, as the survivors improve over
time, but the non-survivors do not. We also see platelet
count as a predictor of outcome both early and late in
the timecourse. Survivors tended to increase platelet
count during the recovery stage, while non-survivors did
not. This matches clinical experience. Interestingly,
platelet transfusion was required in certain patients, but
did not seem to have a major effect closing the observed
gap; we observed a relatively small change in platelet
count for each unit replaced.
Eigengene analysis
Eigengene network
We used WGCNA to infer a gene co-expression net-
work consisting of 19 modules. We labeled the modules
with biologically relevant terms using GO enrichment
analysis (Fig. 3a), which we report in Additional file 1:
Table S2. We also did pathway analyses for each module,
A B C
Fig. 2 Analysis of clinical parameters. We analyzed the evolution of clinical parameters over time. (a) We projected the timepoint medians onto the
leading principal components of the phenotype, and charted the median timecourse (blue) on a biplot. We then separated out the survivors (green)
and non-survivors (red), and note a clear separation along the SOFA and MELD-XI dimensions. (b) We heatmapped median values at each timepoint.
Each row is scaled to z-scores to bring out temporal contrasts, where red is upregulated and green is downregulated. On day 1 following surgery, we
see the SOFA score peak, the platelet count, temperature, and respiratory rate trough. The white blood cell count reaches a maximum on day = +3,
and then recovery occurs on day +5 and +8 as the platelet count rises and the SOFA score decreases. (c) We fit univariate Cox models for each clinical
parameter at each timepoint, made a heatmap using signed –log p values (where the sign comes from the model coefficient), and displayed corrected
q-values below q < 0.2. Notice that, with time, the organ dysfunction scores become highly predictive of survival (top right). Platelet count
is also moderately predictive of survival, both at later points and before surgery
Table 2 Summary of timecourse features
Day −1 Day +1 Day +3 Day +5 Day +8
Upregulated
phenotype
MELD-XI, bilirubin,
temperature, PaO2/FiO2
SOFA, creatinine WBC MAP, INR, platelets Platelets, temperature,
INR, glucose, respiratory
rate
Downregulated
phenotype
WBC, MAP Respiratory rate, temperature,
platelets, MAP, PaO2/FiO2
Glucose, INR MELD-XI, SOFA,
creatinine, glucose,
heart rate
SOFA, bilirubin, creatinine
Upregulated
eigengene
Type I IFN, Transcription Metabolic, mitochondria, innate B cells,
transcription
Mitosis, Defense, RNA
processing
Apoptosis, protein
folding, coagulation,
catabolism
Downregulated
eigengene
Mitosis, catabolism,
defense, mitochondria,
ribosome
T cells, demethylation, ER,
transcription, coagulation, Type I
IFN, NK cells
Type I IFN,
NK cells
Innate B cells, innate, metabolic,
mitochondria
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and enrichment analyses of transcription factor binding
sites, both of which are summarized in Additional file 1:
Table S3. An in-depth discussion of the modules can be
found in Additional file 1.
To assist in conceptualizing the eigengene network,
we further looked for “superclusters” by clustering the
eigengenes, and color-coded the result (Fig. 3a). Much
of the structure we found can be explained succinctly:
the turquoise supercluster can be understood as the
adaptive immune system, the brown supercluster as
components of the innate immune system, blue as meta-
bolic, green as catabolic, and yellow as reparative. These
supercluster colors are used throughout to aid in inter-
pretation and organization.
Analysis of the cross-correlation between eigengenes
revealed more detailed relationships in the network (Fig.
3b). The most distinctive feature is the strong negative
correlation between the innate and adaptive immune su-
perclusters, a feature that has been previously described
in the literature [23]. We also found strong associations
between these superclusters and the mitochondria mod-
ule, suggesting a link between mitochondrial function
and innate immunity. Mitochondria are recognized as
principal mediators of inflammation and arbitrators of
the pro-inflammatory state [30], have been characteris-
tically studied in the context of organ dysfunction, and
play a critical role in tissue hypoxia and production of
reactive oxygen species [31–33]. Mitochondrial products
have also been proposed as damage-associated molecular
pattern (DAMP) signals [34] [35]. As we will see in the
time-dependent analysis, the mitochondria and innate
immune eigengenes peak together within the first 24 h
after surgery. This coincidence suggests temporally or-
chestrated interactions between the two modules.
Mapping eigengenes to clinical parameters
We uncovered relationships between the eigengenes and
the clinical parameters using a linear mixed-effect
model, and identified structure by bi-clustering the
eigengenes with the clinical parameters (Fig. 4). Organ
dysfunction, as measured by the SOFA and MELD-XI
scores (along with creatinine, glucose, and white blood
cell counts), is positively associated with the innate im-
munity, metabolic, and mitochondria modules. Con-
versely, organ dysfunction is negatively associated with
the adaptive immunity supercluster, particularly the T
cell, B cell, NK cell, Type I IFN, and transcription mod-
ules. This antagonistic pattern is consistent with previ-
ously reported innate activation and T-cell suppression
[23], and believed to be causal: as innate-immunity-
associated inflammation increases, organ dysfunction
worsens, and the innate immune system suppresses the
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Fig. 3 WGCNA network. (a) The WGCNA network has 19 modules, which we labeled using gene ontology enrichment analysis. To simplify the
representation further, we hierarchically clustered the eigengenes to identify 5 superclusters, and color-coded them with distinct colors. Here, the
turquoise supercluster can be understood as the adaptive immune system, the brown supercluster as components of the innate immune system,
blue as a metabolic module, green as a catabolic module, and yellow as a reparative supercluster. The 4 most populated modules are T cells,
catabolism, innate immunity, and mitochondria, all from separate superclusters. (b) WGCNA computes the eigengene network links using
Pearson correlation, which we threshold at r > 0.3 for display. The color of each link indicates positive (red) or negative (green) correlation. The width
of each link is proportional to the magnitude of correlation. The size of each node is proportional to the eigenvector centrality in the network. Notice
the strong negative correlations between the innate and adaptive immune superclusters, the positive correlations of the mitochondria module with
the innate module, and the negative correlations of the mitochondria module with the adaptive immune supercluster. The demethylation module is
relatively disconnected, and is comprised mostly of Y-chromosome genes
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adaptive immune system. Conversely, as inflammation is
suppressed and the adaptive immune system function
returns, organ dysfunction improves.
We also found these three superclusters had signifi-
cant associations with the platelet count, which is a par-
ameter that contributes to the SOFA score and is
predictive of survival. The platelet count had a positive
association with the T cell, NK cell, type I IFN, and co-
agulation modules, and a negative association with the
metabolic, innate, and mitochondria modules.
If we assume in concordance with published literature
that 1) organ dysfunction is mediated by specific inter-
action patterns between leukocytes, EC and PLT, 2)
more innate inflammation is associated with “more
sticky” EC and PLT, and 3) more PLT-clot leads to more
PLT-consumption, our transcriptome-phenome data
point towards an orchestrated system-wide behavior that
either “cools down” to allow recovery and survival or
further escalates “out of control” towards death.
Finally, we found an association between glucose levels
and organ dysfunction scores, which is also consistent
with the literature. Higher glucose levels have been asso-
ciated, likely via increased adreno-cortical drive, with an
increased 30-day mortality rate in conditions such as
acute heart failure [36, 37].
Time-dependent eigengene analysis
We expected to see distinctive time-dependent features
in the transcriptome, because the surgery is a significant
perturbation to the system that is already characterized
by AdHF-induced changes, and the recovery is very dy-
namic. As with the clinical parameters, we characterized
these features by examining how the median eigengene
levels changed over time.
Fig. 4 Mapping eigengenes to phenotypes. We inferred relationships between eigengenes and clinical parameters using a linear mixed-effect
model, accounting for within-patient variance, and controlling for age, sex, race, diabetes, ischemic etiology, platelet transfusion, device type,
plasmapheresis, and immunosuppression. We bi-clustered on the signed -log p-values to identify patterns, while displaying significant q-values.
Note that the SOFA and MELD-XI scores are positively correlated with the innate (brown) and metabolic (blue) superclusters, and negatively
correlated with the adaptive (turquoise) superclusters. Conversely, platelet count is positively correlated with the adaptive (turquoise) supercluster,
while negatively correlated with the innate (brown) supercluster. Finally, the mitochondria module, which relates to both immunity superclusters,
is associated with multiple indicators of organ failure
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Principal component analysis revealed differences be-
tween survivors and non-survivors, and their eigengene
trajectories over time. In the biplot (Fig. 5a), the orienta-
tion of the eigengene vectors reflects the superclustering
we have previously noted, where the innate and adaptive
immune system are antiparallel, with the remaining
eigengenes acting orthogonally to both. We notice a net
displacement from day −1 to day 8 in the direction of
the reparative and catabolic superclusters, indicative of
the recovery processes activated following the surgery
for all patients. The second timepoint, however, is a
large deviation from that trajectory, which we associate
with activation of the innate immunity supercluster, and
suppression of the adaptive immunity supercluster. This
deviation is much more pronounced in the non-
survivors.
We uncovered a more detailed picture of the
eigengene trajectory by noting how eigengenes peak
at different times (Fig. 5b). We found a genomic re-
sponse to surgery orchestrated into stages: first, acti-
vation of the innate immune response, followed by
anti-inflammation, and finally reparative processes
such as mitosis, coagulation, and apoptosis. These
temporal features are summarized in Table 2, and a
more in-depth discussion can be found in Additional
file 1.
Finally, we discovered more detailed differences be-
tween survivors and non-survivors using a Cox model
(Fig. 5c). We found a consistent effect from the demeth-
ylation module across all timepoints, but suspect this re-
sult is artifactual. The demethylation module is heavily
enriched by Y-chromosome genes, indicating that the ef-
fect is likely due to the fact that all non-survivors were
male. We also found mitosis and defense eigengenes be-
coming predictive late in the timecourse. These features
are related to cellular regeneration and extracellular
matrix (ECM) degradation, and are consistent with
organ failure due to disseminated intravascular coagu-
lopathy (DIC). They are also consistent with the failure
of non-survivors to recover platelet count late in the
time course. A more detailed discussion of these mod-
ules can be found in Additional file 1.
Discussion
Providing the best possible care for AdHF patients re-
quiring advanced therapies such as MCS-surgery as
bridge to recovery, bridge to transplantation or destin-
ation therapy is an important challenge for modern
medicine. The 1-year mortality rate following MCS im-
plantation is relatively high compared to other medical
procedures, in the range of 20% [1]. A better under-
standing and prediction of clinical outcomes requires a
A B C
Fig. 5 Time-dependent eigengene analysis. We analyzed the evolution of eigengene levels over time. (a) We projected the timepoint medians
onto the leading principal components of the eigengene expression, and charted the median timecourse (blue) on a biplot. We then separated
the survivors (green) and non-survivors (red), revealing an exaggerated innate immune and metabolic first step in non-survivors. (b) We made a
heatmap of the median values for each eigengene at each timepoint. Each row is scaled to z-scores to bring out temporal contrasts, where red is
upregulated and green is downregulated. Here, we ordered the rows by sorting z-scores at day 1. We found a response to surgery orchestrated
into stages: first, activation of the innate immune response, followed by anti-inflammation, and finally reparative processes such as mitosis, coagulation,
and apoptosis. (c) To infer which eigengenes are related to survival outcomes, we fit a multivariate mixed-effects Cox model to the eigengenes (asterisks),
and univariate Cox models at each timepoint (uncorrected p-values displayed), and made a heatmap using signed –log p values (where the sign comes
from the model coefficient). Note that the reparative (yellow) supercluster emerges as important in the last two timepoints, along with the Type
I IFN module. The mitosis and defense modules, marked by significant p-values, are related to cellular regeneration and extracellular matrix (ECM)
degradation, and suggest organ failure due to disseminated coagulopathy
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model that accurately captures a multitude of complex
features in the systemic inflammatory response. In this
context, the main results of this study 1) demonstrate a
clear phenome (organ dysfunction)/PBMC-transcrip-
tome-relationship, 2) support a time-dependent evolu-
tion of the PBMC-transcriptome as it relates to survival/
non-survival outcomes, and 3) allow to generate a hy-
pothesis of the role of coagulation-and platelet-related
biology in the survival fate of the AdHF-patient after
MCS-surgery.
The necessity of developing an appropriate conceptual
immunological framework has been stated by various
groups [31, 38], but has been accompanied by significant
challenges. Genome-wide transcription profiling in hu-
man sepsis has indicated that both pro- and anti-
inflammatory mechanisms occur at various times over
the course of sepsis [39, 40], that a patient may cycle
through each phase multiple times [41] and that the
transition from infection with pathogen clearance over
sepsis with organ failure to septic shock with death [42]
calls for a unifying integrated hypothesis linking inflam-
mation, energy metabolism, coagulopathy and organ
dysfunction by studying the interaction between leuko-
cytes, endothelial cells and platelets in a phenotype- and
time-dependent design. There are fundamental problems
for the classical biphasic model [31], which assumes a
systemic inflammatory response syndrome (SIRS)
followed by a compensatory anti-inflammatory response
syndrome (CARS) [43]. Still, recent investigations con-
tinue to build upon this limited model, stating that the
biphasic view “may be a simplistic explanation of a com-
plex disease, yet provides a rational explanation for how
the function of the immune system becomes altered dur-
ing the course of sepsis” [44]. An integrative model that
moves beyond the current SIRS/CARS framework would
be of great use to the study of MCS- related MOD.
In this study, we developed an integrative model by
utilizing a systems biological approach, based on three
research study design assumptions. First, we take the
clinical phenotypic trajectory as the most reliable, rele-
vant, and authoritative framework for modeling molecu-
lar data in a hypothesis-agnostic and discovery-driven
way. Second, we assume that a systems approach, linking
the longitudinal time-series clinical phenotype to the en-
tire transcriptome, is the least reductionist approach to
developing a unified model of inflammation in MOD
[31, 44]. And third, we assert that an integrative model
provides the best framework for generating and inter-
preting novel integrative mechanistic hypotheses regard-
ing pathophysiology, diagnosis, prognosis and treatment
of heart failure.
Integrated research strategies have previously been
suggested by other groups [35, 45] and successfully im-
plemented by our own [20, 21]. By adopting this
strategy, we integrated the current biphasic SIRS/CARS-
model into a more unbiased and comprehensive frame-
work. The distinctive, previously published immuno-
logical features of SIRS/CARS [46] are well-captured by
our model at day 1 and 3, when we note the prominent
innate immune response and its subsequent suppression
and transition to adaptive immunity (Fig. 5b). However,
our model has the advantage of incorporating several
features that the SIRS/CARS model does not readily ac-
commodate. We note a number of eigengenes that act
orthogonally to the innate/adaptive immune response
(Fig. 5a), which we functionally classify as metabolic,
catabolic, and reparative processes [32]. Recovery mech-
anisms emerge as distinctive features in our model, and
are particularly interesting at later timepoints when the
SIRS/CARS framework is no longer helpful (Fig. 5b and
c). In this way, we functionally characterized distinct
stages of recovery (or non-recovery) from MCS surgery,
unifying a number of disparate hypotheses. The result is
clinically relevant to the goal of improving prediction of
adverse events and designing early pre-emptive thera-
peutic interventions.
The data-driven interpretation of our study results,
based on the above assumptions of the clinical
phenotypic trajectory as the most reliable, relevant,
and authoritative framework and longitudinal time-
series approach needs to drill deep into the source
data: In relation to the ultimate endpoint of being
alive or dead at the end of followup, each timepoints
phenotype data have predictive information (more
advanced organ dysfunction predicing a higher likeli-
hood of death). Hypothesizing that our PBMC tran-
scriptome data improve this prediction, our
transcriptome data interpretation must necessarily be
phenotype- and time-dependent. The phenotype- and
time-dependent module eigengenome interpretation
must accept the systems-theoretical “downward-caus-
ation” [47] property of the time-dependent pheno-
type onto the PBMC-module eigengenome. This
interpretative strategy leads us to the following
insights:
1) Attempts of a phenotype- and time-independent in-
terpretation of the PBMC-transcriptome have to be
resisted in order to be effective. This insight may ex-
plain why many of the current critical care interven-
tions aimed at reducing risk of dying in MOD have
so far proven unsuccessful.
2) An iterative algorithmized approach to predict
future phenotype (survival versus death), based on
the time-dependent phenotype (summed up over all
preceding timepoints, refined by the time—and
phenotype-dependent module-eigenegenome) seems
feasible and is a logical strategic step.
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3) Higher SOFA and MELD-XI score on timepoints 4
and 5 and higher mitosis and defense eigengene ex-
pression on timepoints 4 and 5 are associated with
worse subsequent survival (as indicator of biological
need to counteract destabilizing trends), while
higher platelet scores on timepoints 1, 4, 5 and
higher IFN-eigengene expression (as indicator of
adaptive immunity recovery) on timepoint 5 are as-
sociated with better subsequent survival.
4) The following integrated hypothesis emerges: AdHF-
and MCS-induced innate non-specific inflammatory
response is causally linked in various/all organs – via
EC- and PLT-interactions – with energy-inefficiency
(mitochondrial module) and coagulopathy with low
PLT-count and organ dysfunction, likely via micro-
vascular clot formation. If the pattern reverses (indi-
cated by improvement of the SOFA-score, MELD-XI
score, PLT, adaptive immunity modules, the patient’s
probability of survival increases. If it does not re-
verse, the patient’s probability of death increases.
5) We can now hypothesize that in a milieu of chronic
activation of the SNS and RAAS (first level of
compensation) as well as varying degrees of
activation of the immune system (second level of
compensation), the implantation of the longterm
MCS (third level of compensation) (Fig. 1) adds an
unpredictable perturbation to the system. This
added perturbation with its time-dependently acti-
vated and well orchestrated innate inflammatory and
procoagulatory activation (as measured by time-
series PBMC-transcriptome data) and related organ
dysfunction either serves to restore improved oxygen
delivery, “cooling down” of inflammation, resolution
of coagulopathy, normalization of organ function, re-
covery and survival, or escalates and leads to death
(Fig. 6).
Limitations
Control population
While we chose to base this analysis on AdHF-patients
undergoing MCS-surgery alone to address to most
pressing clinical problem of MCS-related perioperative
MOD [1, 7, 8], we acknowledge that we have not ad-
dressed the question which aspects of the PBMC-
biology addressed here is specific to the MCS-surgery
intervention versus related to heart surgery in general.
In order to address this important question, we have ini-
tiated a followup project examining AdHF-cohorts
undergoing A) Optimal Medical Management, B) Heart
transplantation, C) High Risk Coronary Artery Bypass
Surgery and D) healthy volunteers, utilizing the same
study protocol.
Biological validation studies
This study was designed as a hypothesis-generating
study. In our ongoing work, we are generating biological
validation data.
Sample size
While our model was able to accurately identify and in-
tegrate many known features of organ dysfunction fol-
lowing MCS surgery, we acknowledge statistical
limitations due to the small sample size of our dataset.
The small sample size affects the predictive modeling as-
pect of our study, most particularly the Cox survival
models, while the unsupervised approach based on
Fig. 6 Hypothesis Linking PBMC-Mediated Inflammation, Organ Dysfunction and Death: In heart failure (HF)-patients requiring mechanical circulatory
support (MCS) surgery, the time-dependently activated and well orchestrated innate inflammatory activation (as measured by time-series
PBMC-transcriptome data and hypothetical interaction with endothelial cells (EC) and platelets (PLT)) and related organ dysfunction either
serves to restore improved oxygen delivery, “cooling down” of inflammation, normalization of organ function, recovery and survival, or escalates and
leads to death
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WGCNA has been shown in previous studies to be ro-
bust even at small sample sizes (n < 30) [48–50]. Fur-
thermore, because of our repeated-measures design, the
number of total samples used was sufficiently large when
inferring the eigengene network, and when relating it to
the clinical parameters using a linear mixed-effect
model. Thus, most of the statistical limitations in this
experiment arise from the heterogeneity of the small pa-
tient cohort, rather than the inferential methods used in
analysis, which is a limitation that can only be addressed
by expanding our scope to a coordinated multi-center
study to gain a much larger sample size which is cur-
rently being implemented.
Conclusions
Our model identifies and synchronizes, at an interpret-
able level of detail, the many interesting clinical and bio-
logical features in the systemic inflammatory response
following MCS device implantation. It provides an inte-
grative systems biological model, spanning the full
PBMC leukocyte genome, while depicting an orches-
trated molecular trajectory. This biological sequence of
events acts to functionally characterize distinct stages of
recovery from MCS surgery, and can help in under-
standing progressive worsening. This model is also
clinically relevant to exploring and understanding pre-
emptive therapeutic interventions, and to improving pre-
diction of adverse events.
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